For example, percentages of alterations in CAP2, CAP1, CFL1, CFL2, DSTN, ACTB, and ACTG1 genes among prostate cancer varied from 2.6–30% in individual genes (CAP2, 19%; CAP1, 13%; CFL1, 30%; CFL2, 21%; DSTN, 19%; ACTG1, 2.6%; ACTB, 21%;) (Figure 12B, Table 9); the CFL1 gene was amplified predominantly in prostate cancer. This evidence concerns the gene CAP1 and prostate carcinoma.